SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION Financials Saudi Pharmaceutical Industries and Medical Appliances Corporation
Equities
2070
SA0007879188
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.5 SAR | -1.22% |
|
-5.19% | -3.44% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,270 | 4,704 | 4,722 | 2,614 | 4,536 | 4,368 | - | - |
| Enterprise Value (EV) 1 | 4,101 | 5,596 | 5,688 | 3,340 | 5,380 | 5,308 | 5,187 | 5,403 |
| P/E ratio | -7.55 x | 37.7 x | 179 x | -15.8 x | -344 x | 46.4 x | 27.9 x | 20.8 x |
| Yield | - | 2.55% | 1.52% | 2.75% | - | 0.99% | 2.22% | 2.41% |
| Capitalization / Revenue | 2.11 x | 3.02 x | 3.23 x | 1.83 x | 2.74 x | 2.28 x | 2.04 x | 1.81 x |
| EV / Revenue | 2.64 x | 3.59 x | 3.9 x | 2.34 x | 3.25 x | 2.77 x | 2.43 x | 2.24 x |
| EV / EBITDA | 175 x | 23.3 x | 39.6 x | -93.3 x | 29.6 x | 21.1 x | 17.2 x | 14.1 x |
| EV / FCF | 255 x | -36.1 x | - | - | -84.5 x | 61 x | 44.5 x | - |
| FCF Yield | 0.39% | -2.77% | - | - | -1.18% | 1.64% | 2.25% | - |
| Price to Book | 1.69 x | 2.46 x | 2.57 x | 1.7 x | 3.01 x | 2.71 x | 2.54 x | 2.34 x |
| Nbr of stocks (in thousands) | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | - | - |
| Reference price 2 | 27.25 | 39.20 | 39.35 | 21.78 | 37.80 | 36.50 | 36.50 | 36.50 |
| Announcement Date | 3/31/20 | 3/30/21 | 3/31/22 | 3/23/23 | 3/31/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,553 | 1,559 | 1,460 | 1,426 | 1,653 | 1,916 | 2,138 | 2,414 |
| EBITDA 1 | 23.42 | 240.6 | 143.6 | -35.8 | 181.6 | 251 | 302.3 | 383 |
| EBIT 1 | -313.9 | 153.2 | 55.5 | -126.1 | 89.4 | 170.8 | 222.8 | 264.8 |
| Operating Margin | -20.22% | 9.82% | 3.8% | -8.84% | 5.41% | 8.92% | 10.42% | 10.97% |
| Earnings before Tax (EBT) 1 | -446.9 | 158 | - | - | 36.2 | 132.5 | 199.5 | - |
| Net income 1 | -478.6 | 124.8 | - | - | -13.7 | 82 | 154.4 | 268 |
| Net margin | -30.83% | 8% | - | - | -0.83% | 4.28% | 7.22% | 11.1% |
| EPS 2 | -3.610 | 1.040 | 0.2200 | -1.380 | -0.1100 | 0.7861 | 1.307 | 1.758 |
| Free Cash Flow 1 | 16.06 | -155 | - | - | -63.68 | 87 | 116.5 | - |
| FCF margin | 1.03% | -9.94% | - | - | -3.85% | 4.54% | 5.45% | - |
| FCF Conversion (EBITDA) | 68.6% | - | - | - | - | 34.67% | 38.54% | - |
| FCF Conversion (Net income) | - | - | - | - | - | 106.1% | 75.47% | - |
| Dividend per Share 2 | - | 1.000 | 0.6000 | 0.6000 | - | 0.3622 | 0.8097 | 0.8789 |
| Announcement Date | 3/31/20 | 3/30/21 | 3/31/22 | 3/23/23 | 3/31/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|---|
| Net sales 1 | 532 | 409 | 382 | 330.7 | 632 |
| EBITDA | - | - | - | - | - |
| EBIT | - | - | - | - | - |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income 1 | 57 | 22 | -38 | - | 73 |
| Net margin | 10.71% | 5.38% | -9.95% | - | 11.55% |
| EPS | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 5/16/23 | 8/8/23 | 11/6/23 | 3/31/24 | - |
1SAR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 831 | 892 | 966 | 726 | 844 | 940 | 819 | 1,035 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 35.48 x | 3.706 x | 6.73 x | -20.29 x | 4.646 x | 3.745 x | 2.709 x | 2.702 x |
| Free Cash Flow 1 | 16.1 | -155 | - | - | -63.7 | 87 | 117 | - |
| ROE (net income / shareholders' equity) | -19.5% | 6.47% | 1.41% | -9.78% | -0.9% | 6.48% | 9.35% | 13.3% |
| ROA (Net income/ Total Assets) | - | - | - | - | -0.35% | 2.18% | 3.43% | - |
| Assets 1 | - | - | - | - | 3,924 | 3,765 | 4,505 | - |
| Book Value Per Share 2 | 16.10 | 16.00 | 15.30 | 12.80 | 12.60 | 13.50 | 14.40 | 15.60 |
| Cash Flow per Share 2 | 2.910 | 0.0800 | 0.7200 | -1.040 | 0.4000 | 0.3800 | 0.8500 | 1.520 |
| Capex 1 | 319 | 165 | 76.2 | 84.6 | 111 | 134 | 118 | 174 |
| Capex / Sales | 20.56% | 10.56% | 5.22% | 5.93% | 6.74% | 6.99% | 5.51% | 7.21% |
| Announcement Date | 3/31/20 | 3/30/21 | 3/31/22 | 3/23/23 | 3/31/24 | - | - | - |
1SAR in Million2SAR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
36.5
SAR
Average target price
36.08
SAR
Spread / Average Target
-1.15%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.44% | 1.18B | |
| +25.93% | 661B | |
| +26.74% | 566B | |
| -6.64% | 352B | |
| +18.87% | 332B | |
| +3.23% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.29% | 145B |
- Stock Market
- Equities
- 2070 Stock
- Financials Saudi Pharmaceutical Industries and Medical Appliances Corporation
